highmark glp-1 coverage The evolving landscape of anti-obesity medication in Medicaid Highmark and Noom collaborate to

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes mellitus and, in some formulations, obesity

Contrave led to a 4.1% greater weight loss than placebo in six randomized controlled trials with 9,949 participants

Due to reductions in appetite associated with GLP-1RA therapy, there is also the potential for consumption of dietary protein to be inadequate

McCoy RG, Herrin J, Swarna KS et al

This change in how your gut works can lead to diarrhea in some people and constipation in others

The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease